Maintained Improvement of Outcomes related to Skin Clearance, Itch, Sleep and Quality of Life with Baricitinib in Adults with Moderate-to-Severe Atopic Dermatitis who were Treated for up to 200 Weeks in a Randomized Trial
In this medfyle
New data from the BREEZE-AD3 extension suggest patients maintain long-term efficacy in skin clearance, itch, sleep, and quality of life with long-term continued use of baricitinib – even when down-titrated.
About this Medfyle
©2024 Infomedica-Medfyle. All rights reserved.
Source: Maintained Improvement of Outcomes related to Skin Clearance, Itch, Sleep and Quality of Life with Baricitinib in Adults with Moderate-to-Severe Atopic Dermatitis who were Treated for up to 200 Weeks in a Randomized Trial. Wollenberg A, et al. Presented at EADV 2024; P0669; Abstract #5624.
The information and data provided is for information purposes only. The author(s) of the original original presentation had no involvement in the creation of this content.
